{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T02:45:51Z","timestamp":1782355551064,"version":"3.54.5"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,12,2]],"date-time":"2021-12-02T00:00:00Z","timestamp":1638403200000},"content-version":"vor","delay-in-days":1,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001713","name":"european and developing countries clinical trials partnership","doi-asserted-by":"publisher","award":["TMA2016SF-1513"],"award-info":[{"award-number":["TMA2016SF-1513"]}],"id":[{"id":"10.13039\/501100001713","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007537","name":"Freie Universit\u00e4t Berlin","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100007537","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Malar J"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>RTS,S\/AS01, the leading malaria vaccine has been recommended by the WHO for widespread immunization of children at risk. RTS,S\/AS01-induced anti-CSP IgG antibodies are associated with the vaccine efficacy. Here, the long-term kinetics of RTS,S\/AS01-induced antibodies was investigated.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>150 participants were randomly selected from the 447 children who participated in the RTS,S\/AS01 phase IIb clinical trial in 2007 from Kilifi-Kenya. Cumulatively, the retrospective follow-up period was 93\u00a0months with annual plasma samples collection. The levels of anti-CSP IgM, total IgG, IgG1, IgG2, IgG3, and IgG4 antibodies were then determined using an enzyme-linked immunosorbent assay.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>RTS,S\/AS01 induced high levels of anti-CSP IgG antibodies which exhibited a rapid waning over 6.5\u00a0months post-vaccination, followed by a slower decay over the subsequent years. RTS,S\/AS01-induced anti-CSP IgG antibodies remained elevated above the control group levels throughout the 7\u00a0years follow-up period. The anti-CSP IgG antibodies were mostly IgG1, IgG3, IgG2, and to a lesser extent IgG4. IgG2 predominated in later timepoints. RTS,S\/AS01 also induced high levels of anti-CSP IgM antibodies which increased above the control group levels by month 3. The controls exhibited increasing levels of the anti-CSP IgM antibodies which caught up with the RTS,S\/AS01 vaccinees levels by month 21. In contrast, there were no measurable anti-CSP IgG antibodies among the controls.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>RTS,S\/AS01-induced anti-CSP IgG antibodies kinetics are consistent with long-lived but waning vaccine efficacy. Natural exposure induces anti-CSP IgM antibodies in children, which increases with age, but does not induce substantial levels of anti-CSP IgG antibodies.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12936-021-03961-2","type":"journal-article","created":{"date-parts":[[2021,12,2]],"date-time":"2021-12-02T15:04:09Z","timestamp":1638457449000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Seven-year kinetics of RTS, S\/AS01-induced anti-CSP antibodies in young Kenyan children"],"prefix":"10.1186","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7209-4614","authenticated-orcid":false,"given":"Robert M.","family":"Mugo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kennedy","family":"Mwai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jedidah","family":"Mwacharo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Faiz M.","family":"Shee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer N.","family":"Musyoki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juliana","family":"Wambua","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward","family":"Otieno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip","family":"Bejon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francis M.","family":"Ndungu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,12,2]]},"reference":[{"key":"3961_CR1","volume-title":"World malaria report 2020: 20 years of global progress and challenges","author":"WHO","year":"2020","unstructured":"WHO. World malaria report 2020: 20 years of global progress and challenges. Geneva: World Health Organization; 2020."},{"key":"3961_CR2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1000406","volume":"8","author":"PL Alonso","year":"2011","unstructured":"Alonso PL, Brown G, Arevalo-Herrera M, Binka F, Chitnis C, Collins F, et al. A research agenda to underpin malaria eradication. PLoS Med. 2011;8: e1000406.","journal-title":"PLoS Med"},{"key":"3961_CR3","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/S0140-6736(15)60721-8","volume":"386","author":"RTS,S Clinical Trial Partnership","year":"2015","unstructured":"RTS,S Clinical Trial Partnership. Efficacy and safety of RTS,S\/AS01 malaria vaccine with or without a booster dose in infants and children in Africa: final results of a phase 3, individually randomised, controlled trial. Lancet. 2015;386:31\u201345.","journal-title":"Lancet"},{"key":"3961_CR4","doi-asserted-by":"publisher","first-page":"90","DOI":"10.4161\/hv.6.1.9677","volume":"6","author":"J Cohen","year":"2010","unstructured":"Cohen J, Nussenzweig V, Vekemans J, Leach A. From the circumsporozoite protein to the RTS, S\/AS candidate vaccine. Hum Vaccin. 2010;6:90\u20136.","journal-title":"Hum Vaccin"},{"key":"3961_CR5","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1038\/nbt1015-1015","volume":"33","author":"C Morrison","year":"2015","unstructured":"Morrison C. Landmark green light for Mosquirix malaria vaccine. Nat Biotechnol. 2015;33:1015\u20137.","journal-title":"Nat Biotechnol"},{"key":"3961_CR6","unstructured":"WHO recommends groundbreaking malaria vaccine for children at risk. Geneva, World Health Organization. 2021. https:\/\/www.who.int\/news\/item\/06-10-2021. Accessed 18 Oct 2021."},{"key":"3961_CR7","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1086\/600120","volume":"200","author":"KE Kester","year":"2009","unstructured":"Kester KE, Cummings JF, Ofori-Anyinam O, Ockenhouse CF, Krzych U, Moris P, et al. Randomized, double-blind, phase 2a trial of falciparum malaria vaccines RTS, S\/AS01B and RTS, S\/AS02A in malaria-naive adults: safety, efficacy, and immunologic associates of protection. J Infect Dis. 2009;200:337\u201346.","journal-title":"J Infect Dis"},{"key":"3961_CR8","doi-asserted-by":"publisher","first-page":"1450","DOI":"10.1016\/S1473-3099(15)00239-X","volume":"15","author":"MT White","year":"2015","unstructured":"White MT, Verity R, Griffin JT, Asante KP, Owusu-Agyei S, Greenwood B, et al. Immunogenicity of the RTS, S\/AS01 malaria vaccine and implications for duration of vaccine efficacy: secondary analysis of data from a phase 3 randomised controlled trial. Lancet Infect Dis. 2015;15:1450\u20138.","journal-title":"Lancet Infect Dis"},{"key":"3961_CR9","doi-asserted-by":"publisher","first-page":"42","DOI":"10.12688\/wellcomeopenres.15002.1","volume":"4","author":"FM Ndungu","year":"2019","unstructured":"Ndungu FM, Mwacharo J, Wambua J, Njuguna P, Marsh K, Drakeley C, et al. A seven-year study on the effect of the pre-erythrocytic malaria vaccine candidate RTS, S\/AS01E on blood stage immunity in young Kenyan children. Wellcome Open Res. 2019;4:42.","journal-title":"Wellcome Open Res"},{"key":"3961_CR10","doi-asserted-by":"publisher","first-page":"2521","DOI":"10.1056\/NEJMoa0807381","volume":"359","author":"P Bejon","year":"2008","unstructured":"Bejon P, Lusingu J, Olotu A, Leach A, Lievens M, Vekemans J, et al. Efficacy of RTS, S\/AS01E vaccine against malaria in children 5 to 17 months of age. N Engl J Med. 2008;359:2521\u201332.","journal-title":"N Engl J Med"},{"key":"3961_CR11","doi-asserted-by":"publisher","first-page":"1111","DOI":"10.1056\/NEJMoa1207564","volume":"368","author":"A Olotu","year":"2013","unstructured":"Olotu A, Fegan G, Wambua J, Nyangweso G, Awuondo KO, Leach A, et al. Four-year efficacy of RTS, S\/AS01E and its interaction with malaria exposure. N Engl J Med. 2013;368:1111\u201320.","journal-title":"N Engl J Med"},{"key":"3961_CR12","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/S0966-842X(01)02278-8","volume":"10","author":"PC Bull","year":"2002","unstructured":"Bull PC, Marsh K. The role of antibodies to Plasmodium falciparum-infected-erythrocyte surface antigens in naturally acquired immunity to malaria. Trends Microbiol. 2002;10:55\u20138.","journal-title":"Trends Microbiol"},{"key":"3961_CR13","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1038\/ni.f.205","volume":"9","author":"J Langhorne","year":"2008","unstructured":"Langhorne J, Ndungu FM, Sponaas A-M, Marsh K. Immunity to malaria: more questions than answers. Nat Immunol. 2008;9:725\u201332.","journal-title":"Nat Immunol"},{"key":"3961_CR14","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1016\/j.immuni.2015.02.012","volume":"42","author":"MJ Boyle","year":"2015","unstructured":"Boyle MJ, Reiling L, Feng G, Langer C, Osier FH, Aspeling-Jones H, et al. Human antibodies fix complement to inhibit Plasmodium falciparum invasion of erythrocytes and are associated with protection against malaria. Immunity. 2015;42:580\u201390.","journal-title":"Immunity"},{"key":"3961_CR15","doi-asserted-by":"publisher","first-page":"2425","DOI":"10.1073\/pnas.1621489114","volume":"114","author":"D Kazmin","year":"2017","unstructured":"Kazmin D, Nakaya HI, Lee EK, Johnson MJ, Van Der Most R, Van Den Berg RA, et al. Systems analysis of protective immune responses to RTS, S malaria vaccination in humans. Proc Natl Acad Sci USA. 2017;114:2425\u201330.","journal-title":"Proc Natl Acad Sci USA"},{"key":"3961_CR16","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1186\/s12916-018-1186-4","volume":"16","author":"I Ubillos","year":"2018","unstructured":"Ubillos I, Ayestaran A, Nhabomba AJ, Dosoo D, Vidal M, Jim\u00e9nez A, et al. Baseline exposure, antibody subclass, and hepatitis B response differentially affect malaria protective immunity following RTS, S\/AS01E vaccination in African children. BMC Med. 2018;16:197.","journal-title":"BMC Med"},{"key":"3961_CR17","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1186\/s12916-014-0117-2","volume":"12","author":"MT White","year":"2014","unstructured":"White MT, Bejon P, Olotu A, Griffin JT, Bojang K, Lusingu J, et al. A combined analysis of immunogenicity, antibody kinetics and vaccine efficacy from phase 2 trials of the RTS,S malaria vaccine. BMC Med. 2014;12:117.","journal-title":"BMC Med"},{"key":"3961_CR18","doi-asserted-by":"publisher","first-page":"1742","DOI":"10.1038\/s41467-021-21998-4","volume":"12","author":"G Feng","year":"2021","unstructured":"Feng G, Wines BD, Kurtovic L, Chan J-A, Boeuf P, Mollard V, et al. Mechanisms and targets of Fc\u03b3-receptor mediated immunity to malaria sporozoites. Nat Commun. 2021;12:1742.","journal-title":"Nat Commun"},{"key":"3961_CR19","doi-asserted-by":"publisher","first-page":"1076","DOI":"10.1086\/656190","volume":"202","author":"ST Agnandji","year":"2010","unstructured":"Agnandji ST, Asante KP, Lyimo J, Vekemans J, Soulanoudjingar SS, Owusu R, et al. Evaluation of the safety and immunogenicity of the RTS, S\/AS01E malaria candidate vaccine when integrated in the expanded program of immunization. J Infect Dis. 2010;202:1076\u201387.","journal-title":"J Infect Dis"},{"key":"3961_CR20","doi-asserted-by":"publisher","first-page":"2533","DOI":"10.1056\/NEJMoa0807773","volume":"359","author":"S Abdulla","year":"2008","unstructured":"Abdulla S, Oberholzer R, Juma O, Kubhoja S, Machera F, Membi C, et al. Safety and immunogenicity of RTS, S\/AS02D malaria vaccine in infants. N Engl J Med. 2008;359:2533\u201344.","journal-title":"N Engl J Med"},{"key":"3961_CR21","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.aax4489","volume":"5","author":"MJ Boyle","year":"2019","unstructured":"Boyle MJ, Chan JA, Handayuni I, Reiling L, Feng G, Hilton A, et al. IgM in human immunity to Plasmodium falciparum malaria. Sci Adv. 2019;5: eaax4489.","journal-title":"Sci Adv"},{"key":"3961_CR22","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1016\/j.immuni.2016.06.014","volume":"45","author":"AT Krishnamurty","year":"2016","unstructured":"Krishnamurty AT, Thouvenel CD, Portugal S, Keitany GJ, Kim KS, Holder A, et al. Somatically hypermutated Plasmodium-specific IgM+ memory B cells are rapid, plastic, early responders upon malaria rechallenge. Immunity. 2016;45:402\u201314.","journal-title":"Immunity"},{"key":"3961_CR23","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofv118","volume":"2","author":"C Arama","year":"2015","unstructured":"Arama C, Skinner J, Doumtabe D, Portugal S, Tran TM, Jain A, et al. Genetic resistance to malaria is associated with greater enhancement of immunoglobulin (Ig) M than IgG responses to a broad array of Plasmodium falciparum antigens. Open Forum Infect Dis. 2015;2: ofv118.","journal-title":"Open Forum Infect Dis"},{"key":"3961_CR24","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20200901","volume":"218","author":"CS Hopp","year":"2021","unstructured":"Hopp CS, Sekar P, Diouf A, Miura K, Boswell K, Skinner J, et al. Plasmodium falciparum\u2014specific IgM B cells dominate in children, expand with malaria, and produce functional IgM. J Exp Med. 2021;218: e20200901.","journal-title":"J Exp Med"},{"key":"3961_CR25","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1038\/s41541-020-0192-7","volume":"5","author":"L Sanchez","year":"2020","unstructured":"Sanchez L, Vidal M, Jairoce C, Aguilar R, Ubillos I, Cuamba I, et al. Antibody responses to the RTS,S\/AS01(E) vaccine and Plasmodium falciparum antigens after a booster dose within the phase 3 trial in Mozambique. NPJ Vaccines. 2020;5:46.","journal-title":"NPJ Vaccines"},{"key":"3961_CR26","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1016\/j.chom.2020.07.001","volume":"28","author":"HA McNamara","year":"2020","unstructured":"McNamara HA, Idris AH, Sutton HJ, Vistein R, Flynn BJ, Cai Y, et al. Antibody feedback limits the expansion of B cell responses to malaria vaccination but drives diversification of the humoral response. Cell Host Microbe. 2020;28:572\u201385.","journal-title":"Cell Host Microbe"},{"key":"3961_CR27","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1186\/s12916-019-1277-x","volume":"17","author":"L Kurtovic","year":"2019","unstructured":"Kurtovic L, Agius PA, Feng G, Drew DR, Ubillos I, Sacarlal J, et al. Induction and decay of functional complement-fixing antibodies by the RTS,S malaria vaccine in children, and a negative impact of malaria exposure. BMC Med. 2019;17:45.","journal-title":"BMC Med"},{"key":"3961_CR28","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1016\/j.molimm.2015.03.255","volume":"67","author":"V Irani","year":"2015","unstructured":"Irani V, Guy AJ, Andrew D, Beeson JG, Ramsland PA, Richards JS. Molecular properties of human IgG subclasses and their implications for designing therapeutic monoclonal antibodies against infectious diseases. Mol Immunol. 2015;67:171\u201382.","journal-title":"Mol Immunol"},{"key":"3961_CR29","doi-asserted-by":"publisher","first-page":"439","DOI":"10.3389\/fimmu.2019.00439","volume":"10","author":"C Doba\u00f1o","year":"2019","unstructured":"Doba\u00f1o C, Santano R, Vidal M, Jim\u00e9nez A, Jairoce C, Ubillos I, et al. Differential patterns of IgG subclass responses to Plasmodium falciparum antigens in relation to malaria protection and RTS,S vaccination. Front Immunol. 2019;10:439.","journal-title":"Front Immunol"},{"key":"3961_CR30","doi-asserted-by":"publisher","first-page":"2519","DOI":"10.1056\/NEJMoa1515257","volume":"374","author":"A Olotu","year":"2016","unstructured":"Olotu A, Fegan G, Wambua J, Nyangweso G, Leach A, Lievens M, et al. Seven-year efficacy of RTS, S\/AS01 malaria vaccine among young African children. N Engl J Med. 2016;374:2519\u201329.","journal-title":"N Engl J Med"},{"key":"3961_CR31","doi-asserted-by":"publisher","first-page":"22","DOI":"10.12688\/wellcomeopenres.16524.2","volume":"6","author":"JJ Valletta","year":"2021","unstructured":"Valletta JJ, Addy JW, Reid AJ, Ndungu FM, Bediako Y, Mwacharo J, et al. Individual-level variations in malaria susceptibility and acquisition of clinical protection. Wellcome Open Res. 2021;6:22.","journal-title":"Wellcome Open Res"},{"key":"3961_CR32","doi-asserted-by":"publisher","first-page":"79","DOI":"10.12688\/wellcomeopenres.16562.1","volume":"6","author":"JW Addy","year":"2021","unstructured":"Addy JW, Bediako Y, Ndungu FM, Valetta JJ, Reid AJ, Mwacharo J, et al. 10-year longitudinal study of malaria in children: insights into acquisition and maintenance of naturally acquired immunity. Wellcome Open Res. 2021;6:79.","journal-title":"Wellcome Open Res"}],"container-title":["Malaria Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12936-021-03961-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12936-021-03961-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12936-021-03961-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,2]],"date-time":"2021-12-02T15:05:42Z","timestamp":1638457542000},"score":1,"resource":{"primary":{"URL":"https:\/\/malariajournal.biomedcentral.com\/articles\/10.1186\/s12936-021-03961-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12]]},"references-count":32,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["3961"],"URL":"https:\/\/doi.org\/10.1186\/s12936-021-03961-2","relation":{},"ISSN":["1475-2875"],"issn-type":[{"value":"1475-2875","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,12]]},"assertion":[{"value":"31 July 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 October 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 December 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The main study (i.e., phase IIb clinical trial in 2007) had obtained ethical approval from the Kenya Medical Research Institute National Ethical Committee, the Western Institutional Review Board in Seattle, the Central Oxford Research Ethics Committee, and the London School of Hygiene and Tropical medicine Ethics Committee. Written informed consent for the extension study and sample collections was obtained from parents or guardians of all the children with the use of approved consent forms in (Swahili or Giriama). The extended follow-up study received ethical clearance from the Scientific and Ethics Review Unit-Kenya Medical Research Institute (SERU\/KEMRI\/2887).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"452"}}